Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML-DS-2025: Therapy for AML in Down Syndrome
NCT07232134Phase 3Recruiting
- Sponsor
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
- Start
- Jul 2025
- Primary completion
- Jul 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cytarabine, idarubicin, etoposide, daunorubicin in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Started Jul 2025; status: recruiting.
02
Drugs
cytarabineidarubicinetoposidedaunorubicin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07232134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07232134.